Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.17 USD
+0.78 (0.69%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.17 USD
+0.78 (0.69%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
by Zacks Equity Research
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.
Charles River (CRL) Q4 Earnings Surpass, Margins Contract
by Zacks Equity Research
Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.
DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.
Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
by Zacks Equity Research
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.
DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands
by Zacks Equity Research
Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
by Zacks Equity Research
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
by Zacks Equity Research
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.
McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up
by Zacks Equity Research
STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.
Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands
by Zacks Equity Research
QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.
GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve
by Zacks Equity Research
GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.
5 Broker-Loved Stocks to Watch Amid Current Market Swings
by Maharathi Basu
We believe that stocks like American Airlines (AAL), Delta Air Lines (DAL), Cleveland-Cliffs (CLF), Best Buy (BBY) and Cardinal Health (CAH) should be on an investor's watchlist.
Jobless Claims Increased More Than Expected
by Zacks Equity Research
Jobless Claims Increased More Than Expected
Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow
by Zacks Equity Research
Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.